While high-risk genetic factors (t(4;14, del(17p)(p53) deletion, or 13q deletion) did not affect the response or survival of refractory/relapsed MM patients treated with bortezomib [27], del(17p)(p53) deletion had a negative influence on progression free and overall survival of MM patients receiving lenalidomide and dexamethasone [28]. This evidence concerns the gene TP53 and Miyoshi myopathy.